CBD Life Sciences Inc.
CBDL · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -25.90 | 946.87 | 30.83 |
| FCF Yield | -37.65% | 0.00% | -0.00% | -0.04% |
| EV / EBITDA | -2.20 | -17,685.18 | -50,488.49 | -2,397.78 |
| Quality | ||||
| ROIC | -192.86% | -19.91% | -282.99% | -375.70% |
| Gross Margin | -9.08% | -18.31% | -174.90% | -250.18% |
| Cash Conversion Ratio | 0.77 | 0.21 | 1.11 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.08% | 41.29% | -10.82% | -9.38% |
| Free Cash Flow Growth | -29,879.37% | 100.19% | 80.67% | -960.47% |
| Safety | ||||
| Net Debt / EBITDA | 0.01 | 0.11 | 0.00 | 0.20 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.73 | 9.50 | 54.25 | 4.50 |
| Cash Conversion Cycle | 97.73 | 38.44 | 6.73 | 81.08 |